摘要
目的 :介绍白三烯受体拮抗剂的作用进展和临床应用的评价。方法 :采用国内、外文献综述方法。结果和结论 :近年来 ,高选择性白三烯受体拮抗剂进展十分迅速 ,通过抑制白三烯合成和白三烯受体而对抗哮喘 ,对白三烯受体的选择性高 ,有良好的耐受性和药代动力学性质 ,成为一类新型、安全和有效的抗炎和平喘药物 ,在防治成人和
OBJECTIVE:To summarize the aspect of clinical evaluation and progress on leukotrienes D 4 receptor antigonist.METHODS:To collecte medical literatures in recent years at home and abroad.RESULTS & CONCLUSION:Advance in highly selective leukotrienes D 4 receptor antigonist has been swiftly in recent years,it can fight against asthma by inhibiting the synthesis of leukotrienes or antagonizing leukotrienes receptor.It has higher selectivity to leukotrienes D 4 receptor,good tolerance and characters of pharmacokinetics,becoming a new kind of safe and effective drugs in antiinflammation and antiasthma. Leukotrienes D 4 receptor antagonist now has been playing an important roles in prevention and long-term therapy of asthma for adults and children over 12 years old.
出处
《中国医院用药评价与分析》
2003年第2期75-77,共3页
Evaluation and Analysis of Drug-use in Hospitals of China
